Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9
- 1 August 1996
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (9) , 1518-1522
- https://doi.org/10.1016/0959-8049(96)00120-7
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Limited-sampling models for anticancer agentsZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09JNCI Journal of the National Cancer Institute, 1994
- EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsEuropean Journal Of Cancer, 1993
- Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.Journal of Clinical Oncology, 1993
- Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodentsInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer DrugsClinical Pharmacokinetics, 1989
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979